Identification and quantification of tumour associated molecular markers is important in diagnostics and treatment response monitoring of malignant diseases. Highly sensitive assays are established and commercially available for quantification of recurrent hotspot mutations and fusion transcripts in common cancer types.
contravenes general recommendations that short amplicons should be targeted in real-time quantitative PCR, to ensure highly efficient amplification. To overcome these limitations, we evaluated large amplicon droplet digital PCR (laddPCR), using breakpoint spanning primers, in combination with double quenched probes, for quantification of genomic BCR-ABL1 fusion sequences in pediatric patients with chronic myeloid leukaemia (CML).
Ultra-sensitive MRD assessment has become of increasing interest for patients with CML, since it was demonstrated that tyrosine kinase inhibitor treatment can be stopped indefinitely for some patients who achieve sustained deep molecular remission (DMR) for a prolonged period; however, identification of patients with the highest likelihood of continuous treatment-free remission remains challenging. Approximately half of all individuals with CML develop disease relapse shortly after discontinuation of tyrosine kinase inhibitor (TKI) treatment, 1, 2 indicating that a substantial number of quiescent CML cells remain at the time of treatment cessation, subsequently giving rise to the relapse. In addition to the well-established methods and certified commercial techniques available for high sensitivity monitoring of BCR-ABL1 transcripts, 5, 6 application of DNA-based monitoring may be a useful adjuvant tool to aid treatment decisions 8, 9 ; however, the breakpoint cluster region in the ABL1 gene locus on chromosome 9 is particularly rich in repeat elements, and genomic breakpoints in pediatric patients with CML are (in contrast with those of adult CML patients) over-represented within Alu repeats in the BCR breakpoint cluster region on chromosome 22. 12, 13 These features represent challenges for the establishment of quantification assays with high specificity and sensitivity for these patients.
Here, we analysed the distribution of genomic breakpoints 
| MATERIAL S AND ME THODS

| Patients and materials
| Sequencing of genomic BCR-ABL1 fusion sites
DNA was isolated using the QIAamp ® DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions.
Genomic fusion sequences were identified using a nested multiplex long-range PCR (MLR-PCR) assay, as described previously. 12 
| Analysis of breakpoint characteristics
Patient-specific BCR-ABL1 fusion sequences were aligned to the human genome (hg19, UCSC Genome Browser). Breakpoint positions are listed in Table S1 . Repeat elements at the fusion sites were identified using the RepeatMasker tool (http://www.repeatmasker. 
| Statistical analysis
Co-localization of genomic breakpoints with repeat regions and DNA sequence motifs was statistically analysed using the Fisher's exact test. Differences between the ratio of mRNA% (BCR-ABL1 transcript/ABL1 transcript) and DNA% (BCR-ABL1 fusion gene/ALB gene) at the day of diagnosis and 3 months after treatment initiation were assessed using the Mann-Whitney U-test. MRD data from quantification of the BCR-ABL1 fusion at the RNA and DNA levels were compared using Spearman correlation statistics.
| RE SULTS
| Localization of BCR and ABL1 breakpoints in repeat regions
Kernel density analyses of 178 genomic BCR-ABL1 fusion sequences from pediatric CML samples (breakpoint positions listed in Table S1) confirmed a bimodal distribution of genomic breakpoints within the In the next step, BCR-ABL1 fusion sequences were quantified in individual genomic DNA samples from 55 patients with pediatric CML. Primers were positioned beyond the usual amplicon length region of 150 bp in 26 (47%) cases, to avoid binding to a repeat element on either side of the breakpoint. As expected, the distance between amplicon-positive and -negative droplets was reduced when very large amplicons were generated ( Figure 2D ). Nevertheless, the sensitivity of assays remained high, even for quantification of large amplicons (>1000 bp) ( Figure 2E ).
Reduced signal amplitudes of amplicon-positive droplets were easily compensated for using double quenched probes, which enabled stringent separation between amplicon-positive and -negative droplets ( Figure 2F ).
| Comparative quantification of genomic BCR-ABL1 fusion genes and BCR-ABL1 fusion transcripts
To evaluate the potential clinical application of DNA-based MRD monitoring for CML patients with genomic breakpoints within, and adjacent to, repeat regions, we compared DNA-based quantification with standard RNA-based monitoring. Amplicon lengths varied from 80 to 1330 bp for DNA-based quantification by ddPCR.
We compared 687 blood or bone marrow samples collected from 55 patients with pediatric CML at initial diagnosis and during the course of treatment. Of those 687 samples, 47 were negative at the DNA and RNA levels, while six samples were quantifiable by RT-qPCR, but not using the DNA-based assay. Conversely, the DNAbased assay was able to quantify 64 samples that tested negative at the RNA level ( Figure 3A) . Insufficient RNA quality, due to incorrect In addition, we investigated whether the RNA transcript/ DNA fusion site ratio at diagnosis and 3 months after treatment reflected differences between good and poor responders to TKI treatment. Good responders (MR1.0, <10%, achieved 3 months after treatment initiation and MR3.0, < 0.1%, reached within 12 months of treatment initiation) exhibited lower BCR-ABL1 expression ratios than poor responders ( Figure S2 ). Considering the fusion transcript type, patients with b3a2 transcripts had lower BCR-ABL1 expression ratios those with b2a2 transcripts at the day of initial diagnosis (P = 0.042), which is in contrast to results reported for adult patients. 17 These findings require confirmation in larger cohorts. In pediatric CML specifically, the proportion of individual fusion sites within repeat elements is very high. In addition to the high content of repeat elements within the ABL1 breakpoint cluster region, the bimodal breakpoint distribution within the BCR breakpoint cluster region results in a high co-localization of breakpoints with Alu repeats. 12, 13 For specific quantification of these individual genomic fusion sequences, primers must be positioned outside of the repeat CML. 8, 9, 19, 20 Furthermore, this combined approach allows the study of BCR-ABL1 expression differences during the course of treatment, which may help to predict therapy outcome. 17 Digital PCR is an end-point PCR that enables absolute quantification of nucleic acids by Poisson statistical analysis of amplicon-positive and -negative droplets, without the need for standard curves. 22 Compared with well-standardized real-time PCR assays, ddPCR has equivalent sensitivity but exhibits higher robustness to PCR variations influencing amplification efficiency. This feature results in improved reproducibility and increased sensitivity, particularly when primers/probes have to be designed to target sequences with unfavourable composition. 23 In this study, we optimized laddPCR for highly specific and sensitive assays generating amplicons up to 1330 bp, to enable the quantification of BCR-ABL1 fusion sequences in patients with fusion sites within or adjacent to repeat-rich DNA stretches.
To date, laddPCR has been tested using EvaGreen dye, with moderate results. As the EvaGreen signal is proportional to the amount of double-stranded DNA, an increase in the fluorescent signal with increasing amplicon length is expected, and could be observed in amplicons up to 300 bp. Amplicons longer than 300 bp showed a significant decrease in amplitude, with an accompanying loss of sensitivity, indicating that long products may be incompletely amplified. 24, 25 Probe-based assays for laddPCR should not be affected by this problem. Laurie et al tested amplicons up to 860 bp, with reliable amplitude levels for digital quantification of sequencing libraries, and observed a substantial reduction in positive droplets and hence decreasing sensitivity. 26 In this study, we optimized laddPCR assays using double quenched probes. Using this approach, positive and negative droplets were much better separated, and quantification was feasible for large amplicons (>500 bp) with minimal reduction in sensitivity, comparable to routine RNA-based PCR assays. To further improve the sensitivity of our ddPCR, the number of investigated wells per sample could be increased from duplicate to quadruplicate or even more parallel reactions. 7 In summary, the availability of personalized DNA-based therapy monitoring could be increased by quantification of genomic BCR-ABL1 fusion sequences using improved laddPCR with breakpoint spanning primers and double quenched probes. The sensitivity of this approach is comparable to that of established RNA-based qPCR.
Furthermore, laddPCR could be applied for therapy assessment of other chromosomal rearrangement-positive leukaemic diseases, or in solid cancers, for detection of circulating tumour cells.
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